271 related articles for article (PubMed ID: 11253855)
1. Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.
Owens RC
Pharmacotherapy; 2001 Mar; 21(3):301-19. PubMed ID: 11253855
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial-associated QT interval prolongation: pointes of interest.
Owens RC; Nolin TD
Clin Infect Dis; 2006 Dec; 43(12):1603-11. PubMed ID: 17109296
[TBL] [Abstract][Full Text] [Related]
3. Ciprofloxacin-induced acquired long QT syndrome.
Prabhakar M; Krahn AD
Heart Rhythm; 2004 Nov; 1(5):624-6. PubMed ID: 15851230
[TBL] [Abstract][Full Text] [Related]
4. Antimicrobial agents-associated with QT interval prolongation.
Bril F; Gonzalez CD; Di Girolamo G
Curr Drug Saf; 2010 Jan; 5(1):85-92. PubMed ID: 20210724
[TBL] [Abstract][Full Text] [Related]
5. QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs.
Cubeddu LX
Am J Ther; 2003; 10(6):452-7. PubMed ID: 14624285
[TBL] [Abstract][Full Text] [Related]
6. QT prolongation with antimicrobial agents: understanding the significance.
Owens RC
Drugs; 2004; 64(10):1091-124. PubMed ID: 15139788
[TBL] [Abstract][Full Text] [Related]
7. Moxifloxacin-induced QT prolongation and torsades: an uncommon effect of a common drug.
Badshah A; Janjua M; Younas F; Halabi AR; Cotant JF
Am J Med Sci; 2009 Aug; 338(2):164-6. PubMed ID: 19680025
[TBL] [Abstract][Full Text] [Related]
8. Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors.
Bertino JS; Owens RC; Carnes TD; Iannini PB
Clin Infect Dis; 2002 Mar; 34(6):861-3. PubMed ID: 11830802
[TBL] [Abstract][Full Text] [Related]
9. Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy.
Keivanidou A; Arnaoutoglou C; Krommydas A; Papanikolaou G; Tsiptses K; Chrisopoulos C; Kirpizidis C
Cardiol J; 2009; 16(2):172-4. PubMed ID: 19387967
[TBL] [Abstract][Full Text] [Related]
10. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
Lu HR; Yan GX; Gallacher DJ
J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
[TBL] [Abstract][Full Text] [Related]
11. Postoperative QT interval prolongation in patients undergoing noncardiac surgery under general anesthesia.
Nagele P; Pal S; Brown F; Blood J; Miller JP; Johnston J
Anesthesiology; 2012 Aug; 117(2):321-8. PubMed ID: 22692379
[TBL] [Abstract][Full Text] [Related]
12. Drug-induced QT Interval Prolongation in the Intensive Care Unit.
Etchegoyen CV; Keller GA; Mrad S; Cheng S; Di Girolamo G
Curr Clin Pharmacol; 2017; 12(4):210-222. PubMed ID: 29473523
[TBL] [Abstract][Full Text] [Related]
13. Fluconazole-associated QT interval prolongation and Torsades de Pointes in a paediatric patient.
Ünal Yüksekgönül A; Ertuğrul İ; Karagöz T
Cardiol Young; 2021 Dec; 31(12):2035-2037. PubMed ID: 34024302
[TBL] [Abstract][Full Text] [Related]
14. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
Lawrence CL; Pollard CE; Hammond TG; Valentin JP
J Pharmacol Toxicol Methods; 2005; 52(1):46-59. PubMed ID: 15975832
[TBL] [Abstract][Full Text] [Related]
15. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.
Haddad PM; Anderson IM
Drugs; 2002; 62(11):1649-71. PubMed ID: 12109926
[TBL] [Abstract][Full Text] [Related]
16. Common Genetic Variant Risk Score Is Associated With Drug-Induced QT Prolongation and Torsade de Pointes Risk: A Pilot Study.
Strauss DG; Vicente J; Johannesen L; Blinova K; Mason JW; Weeke P; Behr ER; Roden DM; Woosley R; Kosova G; Rosenberg MA; Newton-Cheh C
Circulation; 2017 Apr; 135(14):1300-1310. PubMed ID: 28213480
[TBL] [Abstract][Full Text] [Related]
17. QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.
Kounas SP; Letsas KP; Sideris A; Efraimidis M; Kardaras F
Pacing Clin Electrophysiol; 2005 May; 28(5):472-3. PubMed ID: 15869686
[TBL] [Abstract][Full Text] [Related]
18. Understanding drug-induced torsades de pointes: a genetic stance.
Kannankeril PJ
Expert Opin Drug Saf; 2008 May; 7(3):231-9. PubMed ID: 18462182
[TBL] [Abstract][Full Text] [Related]
19. QT prolongation and safety in the Indian population.
Dabhi J; Mehta A
Curr Drug Saf; 2007 Sep; 2(3):200-3. PubMed ID: 18690968
[TBL] [Abstract][Full Text] [Related]
20. K201, a multi-channel blocker, inhibits clofilium-induced torsades de pointes and attenuates an increase in repolarization.
Hasumi H; Matsuda R; Shimamoto K; Hata Y; Kaneko N
Eur J Pharmacol; 2007 Jan; 555(1):54-60. PubMed ID: 17112502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
